Transgene (LTS:0OCQ) PEG Ratio: N/A (As of Jul. 09, 2026)


LTS:0OCQ Transgene SA LTS:0OCQ
49 GF Score
Price €0.77
GF Value €0.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Transgene's PE Ratio without NRI is 0.00. Transgene's 5-Year EBITDA growth rate is -7.50%. Therefore, Transgene's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Transgene's PEG Ratio or its related term are showing as below:



LTS:0OCQ's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.98
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Transgene  (LTS:0OCQ) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Transgene PEG Ratio Related Terms

Transgene PEG Ratio Historical Data

* Premium members only.

The historical data trend for Transgene's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene PEG Ratio Chart

Transgene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Transgene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0OCQ vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Transgene's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Transgene's PEG Ratio falls into.


LTS:0OCQ
49GF Score
Transgene SA LTS:0OCQ
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Transgene's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-7.50
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Transgene (LTS:0OCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.77 is trading 48.1% above its estimated GF Value™ of €0.52. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for LTS:0OCQ:

  • PEG Ratio: N/A
  • GF Value™: €0.52 vs. price of €0.77 (48.1% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
49GF Score

Get the complete analysis for LTS:0OCQ

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.52
GF Value